, and EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival) study (6) , lower PP was associated with higher mortality. To add to the complexity, left ventricular (LV) EF has recently been shown to importantly modify the association between PP and mortality in HF (7) . In the first investigation of the prognostic value of PP in HF with preserved ejection fraction (HFpEF) from 22 of 31 studies in the MAGGIC (Meta-Analysis Global Group in Chronic Heart Failure) meta-analysis, there was a highly significant interaction between EF category (HFrEF versus HFpEF, categorized at an EF cut off of 50%) and the relationship between PP and 3-year mortality (7). Lower PP was an independent predictor of mortality in HFrEF, but higher PP was related to higher crude mortality in HFpEF, an association that was attenuated after multivariable adjustment. Intriguingly, in subset analyses of acute (versus chronic) HFpEF, as well as HFpEF without atrial fibrillation, lower PP was related to increased mortality risk ( Table 1) .
Against this backdrop of diverse findings in HF, the study by Laskey et al. (8) in this issue of JACC:
Heart Failure is certainly welcome. In the large cohort of hospitalized patients with HF, regardless of EF in the Get With the Guidelines-Heart Failure (GWTG-HF) program, the authors showed that brachial PP at hospital discharge had a U-shaped relationship to 1-year mortality in both HFrEF and HFpEF (defined by an EF cut off of 40%) ( Figure 1 , top panels), with a risk nadir at a PP of 50 mm Hg. In HFrEF, higher PP was independently associated with lower mortality risk when PP was <50 mm Hg but higher mortality risk when PP was $50 mm Hg. In HFpEF, the association between PP and mortality risk did not reach statistical significance when PP was <50 mm Hg, but higher PP was independently related to increased mortality when PP was AF ¼ atrial fibrillation; DBP ¼ diastolic blood pressure; EF ¼ ejection fraction; GWTG-HF ¼ Get With the Guidelines-Heart Failure; HF ¼ heart failure; HFpEF ¼ heart failure with preserved ejection fraction; HFrEF ¼ heart failure with reduced ejection fraction; HR ¼ heart rate; MAGGIC ¼ Meta-Analysis Global Group in Chronic Heart Failure; PP ¼ pulse pressure; SBP ¼ systolic blood pressure.
The U-shaped relationship of PP with mortality in GWTG-HFrEF helps to fill gaps in understanding divergent results from other previous studies.
Beyond considerations of acuity of HF presentation, severity of disease, and LVEF, the absolute PP in previous studies (and hence their positions on the curve in Figure 1 ) may explain some differences in results. For instance, higher mean PP in the upper 2 quartiles of SOLVD (w52.5 mm Hg) places these patients in the ascending limb of the U (above the nadir of 50 mm Hg in Figure 1) . Indeed a direct association between higher PP and increased mortality was observed in SOLVD, driven by the worse survival in the upper 2 PP quartiles (with no survival difference in the lower 2 quartiles as shown in the hazards plot) (2) . In contrast, the inverse association of lower PP with higher mortality in VMAC was seen only in the lowest PP tertile (mean PP of 34 mm Hg), consistent with the descending limb of the U-shaped curve below the nadir of w50 mm Hg. Similarly, in PRIME-II, the inverse association between lower PP and higher mortality was most pronounced in those with PP <45 mm Hg, where mean PP was 34.5 mm Hg.
In both CAPRICORN and EPHESUS, the mean PP was w47 mm Hg in patients with advanced HFrEF, and inverse relationships between PP and mortality were observed.
Importantly, EPHESUS also showed that, whereas PP was inversely related to mortality, carotid-femoral pulse wave velocity (CPWV), a more direct measure of arterial stiffness, was directly related to mortality. In aggregate, these real-world data from the large GWTG-HF cohort serve as a call to mind the PP gap in HF, to carefully consider its hemodynamic significance (beyond arterial stiffening and including LV function), as well as to recognize its prognostic implications in both HFrEF and HFpEF.
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